2022 in Review, 2023 in Sight

Happy New Year from RetinAI! A New Year, new resolutions, new challenges… and a new newsletter! To all of you thinking ‘Please, not another newsletter. Why should I ever read and subscribe to this one too? Here's why:?

Access the latest news in healthcare, ophthalmology, AI and beyond!?

Stay informed about the latest innovations and developments in healthcare, ophthalmology, AI, automation, and data management by subscribing to our newsletter. Delivered directly to your LinkedIn feed, our content includes academic and research articles as well as updates on popular industry topics. Never miss out on RetinAl news, releases, developments or events we're organizing and attending.

2022 in Review - What happened in the industry?

AI - ChatGPT takes it all

There is no doubt that the release of ChatGPT is one of the biggest pieces of news in the field of AI in 2022. Its launch marks a turning point in the development of generative AI, promising far-reaching implications for many domains of science, including healthcare, by bringing Large-Language-Models (LLM) technology to the fingertips of end users like you. However, concerns have been raised about the role of this new tool within different industries. Here’s our suggested readings on the topic:

• A Harvard Business Review Article on the necessity to create new and different kinds of jobs and organizations to truly unlock the potential of ChatGPT. ‘’The question isn’t whether AI will be good enough to take on more cognitive tasks but rather how we’ll adapt.’’
• A perspective on ChatGPT implications in healthcare. According to the author, ChatGPT, and other natural language processing platforms in general, can benefit healthcare in three core areas: patient care and delivery; research, diagnostics, and treatment; clinical and non-clinical workflow. Probably a bit too optimistic, but still an interesting reflection point.?
• A debate on the role of such AI tools in academic literature, and whether it is appropriate or not to cite ChatGPT as an author.

Healthcare - Telemedicine remains a trend post-pandemic

Remote healthcare grew significantly during the pandemic, with an accelerated transition to digital health. Despite several legal, ethical and technological challenges, telemedicine seems to be here to stay.

• Read more on telemedicine and teleophthalmology in our article.
• An interesting McKinsey study demonstrates how healthcare could shift by 2025 thanks to telehealth and care at home strategies.

Ophthalmology -? Finally the first drug for Geographic Atrophy?

• High expectations for the final decision from the FDA for Apellis’ intravitreal pegcetacoplan drug for geographic atrophy (GA). If approved, pegcetacoplan would be the first-ever treatment for geographic atrophy, an irreversible and severe form of dry age-related macular degeneration (AMD) affecting around 5 million people worldwide. Its 24-month results from two separate Phase 3 clinical studies, showed the drug achieved a clinically meaningful reduction in GA lesion growth compared to controls. Apellis is now submitting a Marketing Authorization Application (MAA) to the European Medicines Agency for intravitreal pegcetacoplan. The submission is based on 24-month results from the Phase III DERBY and OAKS studies. Here’s more details on these results.
• Other programs developed by companies like Iveric Bio are showing positive 18-month results from the Gather 1 trial of Zimura (avacincaptad pegol), an inhibitor of complement C5, which is thought to be a key driver of geographic atrophy. Iveric Bio received Breakthrough Designation from FDA in Nov 2022 (read more here).

2022 in Review - What about RetinAI?

Our team is dedicated to preventing treatable vision loss and enabling timely healthcare decisions. Through our tireless efforts, we have made significant strides in improving our solutions for pharmaceutical and clinical stakeholders, ultimately benefiting patients. We are proud of our accomplishments in 2022.

2023 in Sight - what to expect?

AI - AI everywhere but especially in healthcare

• In this article, leaders from various industries, including healthcare, academic experts and ChatGPT answer several questions on predictions for AI trends in 2023 and share their view about what leaders should do and what not to gain value from AI. ‘’2023 could usher in the democratization of AI through governmental initiatives and the use of AI to develop new business models’’
• Here 2023 AI trends in healthcare. ‘’Health care spending on AI software is expected to grow 40% in 2023, from $4.4 billion in 2022 to nearly $6.2 billion in the new year…Medical image analysis is the most popular use case for AI. With a 26% annual growth rate, it will retain the lion’s share of spending, reaching $2.6 billion in AI software spending in 2027.’’

Healthcare - Precision Medicine should not be the future but the now

• BCG highlights the value of personalized healthcare and the must-have’s for a healthcare organization that seeks to develop capabilities in personalized medicine.

Particularly interesting is the concept of the Health Care Personalization Engine as one must-have. Among the components of the Engine: 1) A technology infrastructure, meaning a data infrastructure (the preferred cloud provider’s suite of tools to protect data, build data ingestion pipelines, etc) and a production framework (a cloud-agnostic, scalable solution that enables the design and deployment of production systems). 2) A central data repository to realize interoperability. 3) A machine learning algorithm for identifying the optimal care pathway for a patient

• At RetinAI we strongly believe in the power and importance of precision medicine and we are actively working with our partners to build digital precision medicine solutions to elevate the quality of care. Read more here.

Ophthalmology - Retina Analytic Tools

Joshua Mali , MD, reveals his top five predictions in ophthalmology for 2023 in the Ophthalmology Times. Joshua Mali , MD, believes that retina imaging analytic tools and software will be the new emerging industry blossoming in 2023 and mentions our new platform, Discovery CORE, as an example of one of these powerful technologies. ''With technologies like this and others in the pipeline, retinal specialists will have standardized analysis tools for conditions such as nAMD, GA, retinal vein occlusion, and DME that will refine our current retinal disease management paradigm.''

2023 in Sight - what to expect from RetinAI?

Our 2023 resolutions and goals:?

• With more than one million patient OCT images processed globally, we have generated valuable insights on the condition and health of those patients. We now want to go one step further and apply those insights to expand into new disease areas, using the eye as a window to the rest of the body. More and more research is showing the connection between the health of our eyes and systemic disease areas such as neurodegenerative disorders (like Retinal imaging in Alzheimer's and neurodegenerative diseases, Snyder, P.J. et al.) and vascular conditions (like Predicting myocardial infarction through retinal scans and minimal personal information, Diaz Pinto. A et al). We are committed to supporting doctors, and ultimately patients, with enhanced insights and knowledge from the eyes, to improve diagnosis and treatment of overall health.???
• We will expand the range of certified AI models to support clinicians with automated, expert-level insights and early detection of less common retinal diseases. Stay tuned for more information or contact us if you are interested in early access to this technology.
• Our innovation network is expanding. We are collaborating with leading disease working groups, to support exciting research in so-far untreatable conditions. Get in touch if you wish to contribute or find out how our technology can support your research!
• After having opened our first U.S. office in Boston last year, this year we will be expanding our U.S. team to support growth within the U.S. market, building upon existing collaborations with pharmaceutical companies.

That’s all from the first edition of Healthcare in Motion. Hope you found the content relevant and we are looking forward to your feedback on this first newsletter edition!